#	Pagina
attuale pagina	/open-h2020/projects/200169/index.html
-1	/open-h2020/projects/193685/index.html
-2	/open-h2020/projects/216032/index.html
-3	/open-h2020/projects/194481/index.html
-4	/open-h2020/projects/212652/index.html
-5	/open-h2020/projects/197132/index.html
-6	/open-h2020/projects/223805/index.html
-7	/open-h2020/projects/224854/index.html
-8	/open-h2020/projects/213922/deliverables.html
-9	/open-h2020/projects/193320/deliverables.html

Opendata, web and dolomites

AML-VACCiN SIGNED

Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

AML-VACCiN project word cloud

Explore the words cloud of the AML-VACCiN project. It provides you a very rough idea of what is the project "AML-VACCiN" about.

patients children clinical unmet profile patient standard vaccin minimal acute cell myeloid medical inducing older outcome line orphan iia rare toxic orchestrated companies immunotherapy forefront ultimately dcp powerful ing safe safety irdirc vaccinate enrolment risk internationally shown aml younger institutes treatment renowned selective public residual consolidation approval 001 personalised 45 takes representing data scientists eradicating cured medicinal 85 innovative private remission adults efficacy off leukaemia deadly shelf reduce die mrd induction approximately disease monitoring stage age assemble action biomarker therapy iib proof intended close status relapse treating dc nine preclinical eradicate gt immune dendritic conditional area vaccine designated

Project "AML-VACCiN" data sheet

The following table provides information about the project.

Coordinator	STICHTING VUMC Organization address address: DE BOELELAAN 1117 city: AMSTERDAM postcode: 1081 HV website: www.vumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.amlvaccin.eu
Total cost	8˙278˙716 €
EC max contribution	6˙001˙482 € (72%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-PHC-2015-two-stage
Funding Scheme	RIA
Starting year	2016
Duration (year-month-day)	from 2016-01-01 to 2020-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	STICHTING VUMC STICHTING VUMC Organization address address: DE BOELELAAN 1117 city: AMSTERDAM postcode: 1081 HV website: www.vumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	coordinator	364˙640.00
2	BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH Organization address address: VOLLMERSBACHSTRASSE 66 city: IDAR OBERSTEIN postcode: 55743 website: www.eufets.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (IDAR OBERSTEIN)	participant	2˙057˙500.00
3	IMMATICS BIOTECHNOLOGIES GMBH IMMATICS BIOTECHNOLOGIES GMBH Organization address address: PAUL EHRLICH STR 15 city: TUEBINGEN postcode: 72076 website: www.immatics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (TUEBINGEN)	participant	1˙300˙650.00
4	LINICAL ACCELOVANCE EUROPE BV LINICAL ACCELOVANCE EUROPE BV Organization address address: VICTORIALAAN 15 city: 'S-HERTOGENBOSCH postcode: 5213 JG website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL ('S-HERTOGENBOSCH)	participant	1˙022˙313.00
5	DCPRIME BV DCPRIME BV Organization address address: GALILEIWEG 8 city: LEIDEN postcode: 2333 BD website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	495˙150.00
6	UNIVERSITETET I BERGEN UNIVERSITETET I BERGEN Organization address address: MUSEPLASSEN 1 city: BERGEN postcode: 5020 website: www.uib.no contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (BERGEN)	participant	184˙989.00
7	ACADEMISCH ZIEKENHUIS GRONINGEN ACADEMISCH ZIEKENHUIS GRONINGEN Organization address address: HANZEPLEIN 1 city: GRONINGEN postcode: 9713 GZ website: www.umcg.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (GRONINGEN)	participant	82˙320.00
8	HELSE BERGEN HFHAUKELAND UNIVERSITY HOSPITAL HELSE BERGEN HFHAUKELAND UNIVERSITY HOSPITAL Organization address address: JONAS LIES VEI 65 city: BERGEN postcode: 5021 website: http://www.helse-bergen.no/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (BERGEN)	participant	82˙320.00
9	HELSINGIN YLIOPISTO HELSINGIN YLIOPISTO Organization address address: YLIOPISTONKATU 3 city: HELSINGIN YLIOPISTO postcode: 14 website: www.helsinki.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (HELSINGIN YLIOPISTO)	participant	82˙320.00
10	TECHNISCHE UNIVERSITAET DRESDEN TECHNISCHE UNIVERSITAET DRESDEN Organization address address: HELMHOLTZSTRASSE 10 city: DRESDEN postcode: 1069 website: http://www.tu-dresden.de/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (DRESDEN)	participant	82˙320.00
11	UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ Organization address address: Langenbeckstrasse 1 city: Mainz postcode: 55131 website: http://www.um-mainz.de/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Mainz)	participant	82˙320.00
12	UNIVERSITATSKLINIKUM BONN UNIVERSITATSKLINIKUM BONN Organization address address: VENUSBERG-CAMPUS 1 city: BONN postcode: 53127 website: www.ukb.uni-bonn.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BONN)	participant	82˙320.00
13	UPPSALA UNIVERSITET UPPSALA UNIVERSITET Organization address address: VON KRAEMERS ALLE 4 city: UPPSALA postcode: 751 05 website: www.uu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	participant	82˙320.00
14	STICHTING VU STICHTING VU Organization address address: DE BOELELAAN 1105 city: AMSTERDAM postcode: 1081 HV website: www.vu.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	0.00

Map

Project objective

Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a deadly rare disease that affects both children and adults. Approximately 45% of younger AML patients who are treated will be cured, and in older patients (>60 years of age), 85% will relapse and die within 2 years.

Immunotherapy has great potential for treating MRD and dendritic cell (DC) therapy is at the forefront of immunotherapy. The AML-VACCiN consortium takes this to the next level through clinical development of a highly-innovative DC vaccine - DCP-001 - that can be produced off-the-shelf and has a powerful preclinical and clinical profile. The aim is to vaccinate AML patients that have been brought into remission through standard induction or consolidation therapy, and to eradicate MRD and effectively reduce the risk of relapse.

In a clinical Phase I/IIa study, the DCP-001 vaccine has already shown to be safe, non-toxic and capable of inducing an AML-targeted immune response. DCP-001 is designated as an orphan medicinal product in the EU.

The AML-VACCiN consortium will advance the clinical development of the vaccine from early-stage (current status) towards proof of concept for safety and efficacy in a Phase IIb clinical study (intended outcome of this project). In addition, a biomarker program will be developed that enables more effective treatment monitoring, selective patient enrolment in future studies and ultimately personalised AML treatment. The deliverables resulting from this project can be used to assemble a data package to apply for conditional approval in Europe.

AML-VACCiN is the orchestrated action of three innovative companies and internationally renowned top medical scientists representing nine European medical institutes. In line with the IRDiRC objectives, this public-private consortium can bring a powerful AML-vaccine very close to clinical practice.

Deliverables

List of deliverables.
Document providing the logo and templates for a uniform corporate look	Other	2020-04-23 02:18:27
Communication and dissemination plan	Documents, reports	2020-04-23 02:18:27

Take a look to the deliverables list in detail: detailed list of AML-VACCiN deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Arjan A. van de Loosdrecht, Sandra van Wetering, Saskia J. A. M. Santegoets, Satwinder Kaur Singh, Corien M. Eeltink, Yvonne den Hartog, Malika Koppes, Jorn Kaspers, Gert J. Ossenkoppele, Ada M. Kruisbeek, Tanja D. de Gruijl A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia published pages: 1505-1518, ISSN: 0340-7004, DOI: 10.1007/s00262-018-2198-9	Cancer Immunology, Immunotherapy 67/10	2020-04-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AML-VACCIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AML-VACCIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination